JPS5931345B2 - Method for producing artificial organs sterilized by high-pressure steam - Google Patents
Method for producing artificial organs sterilized by high-pressure steamInfo
- Publication number
- JPS5931345B2 JPS5931345B2 JP54089319A JP8931979A JPS5931345B2 JP S5931345 B2 JPS5931345 B2 JP S5931345B2 JP 54089319 A JP54089319 A JP 54089319A JP 8931979 A JP8931979 A JP 8931979A JP S5931345 B2 JPS5931345 B2 JP S5931345B2
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- artificial organ
- water
- artificial
- sterilization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- External Artificial Organs (AREA)
Description
【発明の詳細な説明】
本発明は、新規な人工臓器の製造方法、すなわち高圧蒸
気滅菌を施された人工臓器の製造方法に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel method for manufacturing an artificial organ, that is, a method for manufacturing an artificial organ subjected to high-pressure steam sterilization.
人工臓器の主体をなすものは、生体の臓器の機能を代替
する機能部である。The main body of an artificial organ is a functional part that replaces the function of a living organ.
人工腎臓、人工肝臓および人工肺等を含む人工臓器は、
生体臓器の物質移動機能を主として代替している。Artificial organs including artificial kidneys, artificial livers, artificial lungs, etc.
It mainly replaces the mass transfer function of living organs.
即ち、生体機能である代謝、調節、排泄、解毒等を、人
工臓器では透析、濾過、吸着、交換等の物理化学的な機
能で補完している。That is, biological functions such as metabolism, regulation, excretion, and detoxification are complemented by physicochemical functions such as dialysis, filtration, adsorption, and exchange in artificial organs.
人工臓器の機能部において、膜は透析、濾過等では主体
となり、また吸着、交換等では保護部材となって、重要
な役割を果している。In the functional parts of artificial organs, membranes play an important role, playing a main role in dialysis, filtration, etc., and acting as a protective member in adsorption, exchange, etc.
膜機能部の形状としては、平膜、チューブ状膜(積層お
よびコイル状タイプを含む)、毛管膜、中空糸膜、およ
びマイクロカプセル膜(吸着剤、交換剤の保護膜)等を
とりうる。The shape of the membrane function part may be a flat membrane, a tubular membrane (including laminated and coiled types), a capillary membrane, a hollow fiber membrane, a microcapsule membrane (a protective membrane for an adsorbent or an exchange agent), and the like.
処理すべき体液(主として血液)と処理流体(透析液等
であるが必要としない場合もある)との間1こ膜を介在
せしめて前記機能を安全かつ効率的に行うように、機能
部は設計製作される。The functional unit is designed to perform the above functions safely and efficiently by interposing a membrane between the body fluid to be processed (mainly blood) and the processing fluid (dialysis fluid, etc., but it may not be necessary). Designed and manufactured.
体外血液量を小さくしかつ血流を滞流させない小型で使
い易い構造が望ましい。A compact and easy-to-use structure that reduces the amount of extracorporeal blood and prevents blood flow from stagnation is desirable.
人工臓器は安全に使用するにあたり、製造段階で細菌に
よる汚染を防ぎ最終的に滅菌した製品となすことが必要
である。In order to use artificial organs safely, it is necessary to prevent bacterial contamination during the manufacturing stage and to ultimately produce sterilized products.
また使用段階で滅菌済製品に前処理を行うことが必要で
ある。It is also necessary to pre-treat the sterilized product before use.
従来、人工臓器は次の2種類の方法で滅菌され使用に供
されている。Conventionally, artificial organs have been sterilized and used using the following two methods.
第1の方法は、製造業者が人工臓器内tこ比較的濃厚な
通常1〜5%濃度のホルムアルデヒド水溶液を充填する
ことにより滅菌して出荷し、使用者が該人工臓器内のホ
ルムアルデヒドを洗浄したのち、佃液側にヘパリン含有
生理食塩液を充填する等の必要な処理を行ってからこれ
を使用する。The first method is that the manufacturer sterilizes the artificial organ by filling it with a relatively concentrated aqueous formaldehyde solution, usually 1 to 5%, and then the user cleans the formaldehyde inside the artificial organ. Afterwards, necessary treatments such as filling the Tsukuda liquid side with a heparin-containing physiological saline solution are performed before use.
第2の方法は、製造業者が乾燥状態の人工臓器に滅菌ガ
ス、例えば滅菌用成分としてlO〜30%濃度のエチレ
ンオキサイドまたはプロピレンオキサイ ドを含有する
ガスを人工臓器内に通ずることにより滅菌して出荷し、
使用者が乾燥状態の人工臓器に生理食塩液を充填し洗浄
を施して、これを患者に使用する。In the second method, the manufacturer sterilizes the dry artificial organ by passing a sterilizing gas into the artificial organ, for example, a gas containing ethylene oxide or propylene oxide at a concentration of lO to 30% as the sterilizing component. shipped,
The user fills the dry artificial organ with physiological saline, washes it, and uses it on the patient.
第1および第2の方法は、滅菌薬剤を用いる典型的な方
法で、他にアルコール、フェノール、ハロゲン、グルタ
ルアルデヒド、第4級アンモニウム塩、クロールへキシ
ジン、過酸化水素、オゾン、次亜塩素酸ナトリウム等を
用いることができる。The first and second methods are typical methods using sterilizing agents, including alcohol, phenol, halogens, glutaraldehyde, quaternary ammonium salts, chlorhexidine, hydrogen peroxide, ozone, and hypochlorous acid. Sodium etc. can be used.
滅菌薬剤の作用は、殺滅すべき病原微生物、菌および芽
胞の蛋白を変性、破壊し、合成、代謝、酵素反応を阻害
し、細胞膜を損傷、破壊する等の機構に基く。The action of sterilizing agents is based on mechanisms such as denaturing and destroying the proteins of pathogenic microorganisms, bacteria, and spores to be killed, inhibiting synthesis, metabolism, and enzymatic reactions, and damaging and destroying cell membranes.
このような薬剤で滅菌した人工臓器を使用するtこあた
っては使用前に充分に滅菌薬剤を洗浄、除去することが
必要であるが、往々にして滅菌薬剤が残留して問題とな
る場合がある。When using artificial organs that have been sterilized with such agents, it is necessary to thoroughly wash and remove the sterilizing agent before use, but the sterilizing agents often remain and cause problems. be.
また人工臓器洗浄後、見掛は上滅菌削の残留が認められ
なくても、膜や吸着剤等の機能部および他の容器部材内
部に吸蔵されていた滅菌薬剤が人工臓器使用時に血液中
に溶出してくるおそれが太きい。In addition, even if there is no apparent residual sterilization after cleaning the artificial organ, sterilization agents stored in functional parts such as membranes and adsorbents and other container components may enter the blood when the artificial organ is used. There is a strong possibility that it will elute.
残留した滅菌薬剤が患者の生体組織に作用し、種種の副
作用、例えば血液成分への影響、アレルギー症状等を起
すことが知られている。It is known that residual sterilization agents act on the patient's living tissues, causing various side effects such as effects on blood components and allergic symptoms.
とくに慢性腎不全患者への長期血液透析等では問題とな
っている。This is particularly a problem in long-term hemodialysis for patients with chronic renal failure.
上述した滅菌薬剤による滅菌の他に、熱滅菌方法がある
。In addition to sterilization using the sterilizing agents mentioned above, there are heat sterilization methods.
この方法は手術用器具等の滅菌法として一般に実施され
ているものである。This method is generally practiced as a method of sterilizing surgical instruments and the like.
例えば第9改正日本薬局力には、高圧蒸気滅菌法として
、115℃で30分間:121’Cで20分間または1
26℃で15分間のいづれかの条件で飽和水蒸気中の加
熱により微生物を殺滅する方法を規矩している。For example, the 9th revised Japanese Pharmacopoeia states that the high-pressure steam sterilization method is 115°C for 30 minutes, 121'C for 20 minutes, or
The method stipulates that microorganisms are killed by heating in saturated steam at 26° C. for 15 minutes.
さらに上記日本薬局力では、80〜100℃の水中また
は流通水蒸気下で24時間毎に1回30〜60分間づつ
3〜5回の加熱を行う間歇滅菌法も記載されている。Furthermore, the above-mentioned Japanese Pharmacy also describes an intermittent sterilization method in which heating is performed 3 to 5 times for 30 to 60 minutes every 24 hours in water or flowing steam at 80 to 100°C.
別に熱滅菌法として乾熱滅菌および煮沸滅菌がある。Other heat sterilization methods include dry heat sterilization and boiling sterilization.
熱滅菌には滅菌薬剤の残留毒性がなく、洗浄等の使用前
処理が容易という利点を有するので、人工臓器に熱滅菌
法が適用し得るならば、極めて好都合である。Heat sterilization has the advantage that there is no residual toxicity of sterilizing agents and that pre-use treatment such as cleaning is easy, so it would be extremely convenient if heat sterilization could be applied to artificial organs.
然しなカ′(ら人工臓器に熱滅菌方法を適用することは
現在まで殆ど行われていない。However, to date, heat sterilization methods have hardly been applied to artificial organs.
この理由は部材、製造、滅菌工程および滅菌後の無菌的
密封、安全性等に困難な問題があったためで、実用に至
らなかったものである。The reason for this was that there were difficult problems with components, manufacturing, sterilization process, aseptic sealing after sterilization, safety, etc., and it was not put into practical use.
我々は、人工臓器の滅菌に、熱滅菌とりわけ高圧蒸気滅
菌を適用すべく鋭意検討の結果、次々に難問を解決して
きた。As a result of intensive research into applying heat sterilization, particularly high-pressure steam sterilization, to the sterilization of artificial organs, we have solved one difficult problem after another.
例えば、部材1こついては、特開昭53−58194号
、同53−61576号及び同53−99694号、製
造、滅菌工程については特開昭53−84394号、同
53−84395号、同53−101889号、特開昭
54−28495号及び同54−28497号、更に無
菌的密封・安全性については特開昭53−99695号
、特開昭54−28496号、実開昭53−15528
9号、同53−161595号および同53−1615
96号に人工臓器の熱滅菌技術が開示されている。For example, regarding member 1, JP-A-53-58194, JP-A-53-61576, and JP-A-53-99694; manufacturing and sterilization processes are JP-A-53-84394, JP-A-53-84395, and JP-A-53-53- 101889, JP-A No. 54-28495 and JP-A-54-28497, and for aseptic sealing and safety, JP-A-53-99695, JP-A-54-28496, and Utility Model Application No. 53-15528.
No. 9, No. 53-161595 and No. 53-1615
No. 96 discloses a heat sterilization technique for artificial organs.
高圧蒸気滅菌人工臓器のうち、滅菌後の製品に水または
水溶液の充填されたタイプについては、前記特開昭53
−84394号、同53−84395号、特開昭54−
28495号及び同53−28496号等に示すように
、安全性が高く使い易い人工臓器を既に完成している。Among high-pressure steam sterilized artificial organs, the type in which the sterilized product is filled with water or an aqueous solution is disclosed in the above-mentioned Japanese Patent Application Laid-Open No. 53
No. -84394, No. 53-84395, JP-A-1983-
As shown in Nos. 28495 and 53-28496, highly safe and easy-to-use artificial organs have already been completed.
これに対し、滅菌後の製品に水または水溶液の充填され
ていないタイプに関しては、末だ実用化なされていない
。On the other hand, products that are not filled with water or an aqueous solution after sterilization have not yet been put to practical use.
そこで、部材について前記公報、製造工程については前
記特開昭53−101889号公報等の技術を駆使して
鋭意検討を進め本発明を完成するに至った。Therefore, the present invention has been completed by making full use of the techniques disclosed in the above-mentioned publications regarding the members and the aforementioned Japanese Patent Application Laid-open No. 101889/1989 regarding the manufacturing process.
従来の人工臓器は、滅菌剤を含まず、使用前の洗浄準備
が短時間で可能である等の利点を有している。Conventional artificial organs have the advantage that they do not contain sterilizing agents and can be prepared for cleaning in a short time before use.
しかし、人工臓器内が液密状態であるため、高圧蒸気滅
菌処理過程では、液の熱膨張収縮を緩衝する特別の手段
を必要とするとか、又製品自体の重量も重くなり、取扱
い、輸送に不便な点がある。However, because the interior of the artificial organ is liquid-tight, special means are required to buffer the thermal expansion and contraction of the liquid during the high-pressure steam sterilization process, and the product itself becomes heavy, making it difficult to handle and transport. There are some inconveniences.
特に寒冷地で保存する場合、人工臓器空隙部内に充填さ
れた水又は水溶液が凍結し、膜が破壊したり、人工臓器
自体に洩れが発生したりしないような管理が必要となる
。In particular, when storing in a cold region, management is required to prevent the water or aqueous solution filled in the cavity of the artificial organ from freezing, destroying the membrane, and preventing leakage from occurring in the artificial organ itself.
こit、ら問題点は全て人工臓器空隙部内tこ充填され
た水又は水溶液に起因することは明らかであり、水又は
水溶液が充填されていない高圧蒸気滅菌人工臓器の出現
が強く要望されていた。It is clear that these and other problems are all caused by the water or aqueous solution filled in the cavity of the artificial organ, and there has been a strong desire for the emergence of an autoclaved artificial organ that is not filled with water or an aqueous solution. .
本発明の目的は、人工臓器の膜部分が水、水溶液により
膨潤・湿潤された状態であるが、人工臓器の容器内部に
水または水溶液が充填されていない状態の滅菌処理され
た人工臓器を提供することである。An object of the present invention is to provide a sterilized artificial organ in which the membrane part of the artificial organ is swollen and moistened with water or an aqueous solution, but the container of the artificial organ is not filled with water or an aqueous solution. It is to be.
本発明による人工臓器は透析膜が乾燥していないから膜
機能、膜性能が維持されている利点があり、人工臓器の
輸送、保管が極めて容易となる。The artificial organ according to the present invention has the advantage that the membrane function and membrane performance are maintained because the dialysis membrane is not dried, and the transportation and storage of the artificial organ is extremely easy.
しかも、使用に際し滅菌薬剤を除去する必要がないから
取扱いが簡便である。Moreover, it is easy to handle since there is no need to remove sterilizing agents before use.
即ち、本発明は、耐熱性を有する人工臓器を高圧蒸気滅
菌処理するに際し、前もって人工臓器を構成する膜機能
部を水又は水溶液)コて膨潤させ、次いでこの人工臓器
(こ飽和水蒸気雰囲気下で高圧蒸気滅菌を実施し、しか
る後人工臓器への水の製着を抑えながら冷却せしめ、必
要に応じて除湿することからなる、膜機能部が実質的に
水または水溶液で膨潤されかつ該人工臓器の容器および
内部空隙が水または水溶液で充填されていないことを特
徴とする高圧蒸気滅菌された人工臓器の製造方法、であ
る。That is, in the present invention, when subjecting a heat-resistant artificial organ to high-pressure steam sterilization, the membrane function part constituting the artificial organ is swollen in advance with water or an aqueous solution, and then the artificial organ is swollen in a saturated steam atmosphere. The membrane function part is substantially swollen with water or an aqueous solution, and the membrane function part is substantially swollen with water or an aqueous solution. A method for producing an artificial organ sterilized by high-pressure steam, characterized in that the container and the internal cavity are not filled with water or an aqueous solution.
本発明を説明する。The present invention will be explained.
本発明における耐熱性とは、人工臓器全体、およびこれ
らを構成する個々の構成要素が40〜130°Cの湿熱
処理に実質的に耐えることを意味する。Heat resistance in the present invention means that the entire artificial organ and the individual components constituting these can substantially withstand moist heat treatment at 40 to 130°C.
耐熱性を有する膜材料として、セルロース、セルロース
エステル、ポリアクリロニトリル、ポリビニルアルコー
ル、芳香族系ポリアミド、ポリカーボネート、ポリスル
ホン及びポリエステル等からなる平膜、毛細管膜及びチ
ューブ膜を挙げ得る。Examples of heat-resistant membrane materials include flat membranes, capillary membranes, and tube membranes made of cellulose, cellulose ester, polyacrylonitrile, polyvinyl alcohol, aromatic polyamide, polycarbonate, polysulfone, polyester, and the like.
また人工臓器の容器等の部材1こ供するものとして、ポ
リカーボネート、ポリ弗化ビニリデン、ポリ−4−メチ
ルペンテン−1、ポリプロピレン。In addition, polycarbonate, polyvinylidene fluoride, poly-4-methylpentene-1, and polypropylene are used for materials such as containers for artificial organs.
ポリアセクール等を挙げ得る。Examples include polysecure.
本発明は、あらかじめ人工臓器の主要な構成要素である
膜機能部を水または水浴液によってあらかじめ膨潤また
は湿潤させておく。In the present invention, a membrane functional part, which is a main component of an artificial organ, is swollen or moistened in advance with water or a water bath.
そして膨潤状態にある膜機能部を有する人工臓器を高圧
蒸気滅菌する。The artificial organ having the membrane function part in a swollen state is then sterilized with high pressure steam.
もし、膜が乾燥状態にある人工臓器を、湿潤処理の如き
前処理なしに、直接高圧蒸気下1こ爆らすと、膜性能に
著しい劣化が起こる傾向がある。If an artificial organ with a dry membrane is directly exposed to high-pressure steam without any pretreatment such as wetting, significant deterioration in membrane performance tends to occur.
特に水または他の物質の透過効率か低下したり、膜の寸
法変化が生じてくる。In particular, the permeation efficiency of water or other substances decreases, and dimensional changes of the membrane occur.
蒸気滅菌に際し起り易い上記の劣化を回避するためには
、高圧高温の蒸気を爆す前に膜材料を膨潤させる必要性
がある。In order to avoid the above-mentioned deterioration that tends to occur during steam sterilization, it is necessary to swell the membrane material before bombarding it with high-pressure, high-temperature steam.
特に膜自体の有つ含水量を、水または水溶液により膨潤
させることによって、最大膜含水率まで到達させるとよ
い。In particular, it is advantageous to reach the maximum membrane moisture content by swelling the membrane itself with water or an aqueous solution.
ここに最大含水率きは、膜材料を100〜110°Cで
乾燥させたとさの恒量(W2)と、該膜材料を12時間
以上常温の水中1こ浸漬し、膜表面の凝着水る濾紙等で
拭い取ったときの重量(W3)とtこおいて、
として表わす。The maximum moisture content here is the constant weight (W2) of the membrane material dried at 100 to 110°C, and the amount of water that adheres to the membrane surface when the membrane material is immersed in water at room temperature for 12 hours or more. The weight (W3) when wiped with filter paper etc. is divided by t and expressed as follows.
即ち、最大膜含水率とは膜表面に凝着水が実質的に凝着
していない状態をいうもの−Cあって、膜−膜間隙、接
触部およびその近傍Eこ僅かに耐着する凝着水を除けは
、膜のみが水または水混液で膨潤した状態である。In other words, the maximum membrane moisture content refers to the state in which there is substantially no adhered water on the membrane surface, and the membrane-to-membrane gap, the contact area, and its vicinity E are the conditions in which the adhered water is only slightly resistant to adhesion. Except for water landing, only the membrane is swollen with water or a water mixture.
本発明の滅菌方法は、まず人工臓器の膜機能部材(平膜
、チューブ膜、中空繊維膜等)等に注射用蒸留水又6i
生食水等の水溶液を注入し、人工臓器を充分洗浄する。In the sterilization method of the present invention, first, the membrane functional members (flat membrane, tube membrane, hollow fiber membrane, etc.) of an artificial organ are sterilized with distilled water for injection or 6 liters of water.
Inject an aqueous solution such as saline to thoroughly clean the artificial organ.
かくして膜部材も充分膨潤した状態となる。In this way, the membrane member also becomes sufficiently swollen.
人工臓器内の水または水溶液を除菌気体で押出して置換
するか、またはこの人工臓器を飽和蒸気雰囲気下もしく
は蒸気通気化【こ置くことにより膜は最大膜含水率に到
達する。Either the water or aqueous solution in the artificial organ is replaced by extrusion with a sterilizing gas, or the artificial organ is placed in a saturated steam atmosphere or with steam aeration, whereby the membrane reaches its maximum membrane water content.
勿論、乾燥している状態の人工臓器を、飽和蒸気の雰囲
気乃至通気1こよって、膜部材の膨潤状j態となし得る
。Of course, a dry artificial organ can be brought into the swollen state of the membrane member by applying a saturated steam atmosphere or ventilation.
次いで、膜部材が膨潤状態)こある人工臓器を高圧蒸気
下に所定の時間置き滅菌を施す。Next, the artificial organ (in which the membrane member is swollen) is placed under high-pressure steam for a predetermined period of time to sterilize it.
高圧蒸気滅菌装置は公知のオートクレーブが使用できる
。A known autoclave can be used as the high-pressure steam sterilizer.
滅菌処理後、人工臓器の内温に対応する飽和蒸気圧を維
持しながら、オートクレーブの降温降圧を竹う。After sterilization, the autoclave is used to lower the temperature and pressure while maintaining the saturated vapor pressure corresponding to the internal temperature of the artificial organ.
この人工臓器の冷却過程で、オートクレーブ内の蒸気の
一部を乾燥空気と置換して、人工臓器が高圧蒸気滅菌処
理時に吸水した熱量に相当する凝着水分を除去すること
ができる。During the cooling process of the artificial organ, a portion of the steam in the autoclave is replaced with dry air, making it possible to remove condensed moisture equivalent to the amount of heat absorbed by the artificial organ during high-pressure steam sterilization.
乾燥空気の置換量を調整することによって、膜部材の膜
含水率を適宜選促できる。By adjusting the amount of dry air replaced, the membrane moisture content of the membrane member can be appropriately selected.
本発明は人工臓器の内部(こある空隙部分に蒸気処理を
伴う水(水溶液)が残存しない程度に冷却する必要があ
る。In the present invention, it is necessary to cool the interior of the artificial organ to such an extent that water (aqueous solution) accompanying steam treatment does not remain in the void area.
同時に膜部材が必要以上に乾燥して性能の劣化つ≦起ら
ない程度の膜含水率としなければならない。At the same time, the moisture content of the membrane must be such that the membrane member does not dry out more than necessary and its performance deteriorates.
滅菌後の冷却過程の状態を観察しながら、乾燥空気の量
を調整するものである。The amount of dry air is adjusted while observing the cooling process after sterilization.
本発明の効果は、水または水溶液の充填された蒸気滅菌
処理タイプの人工臓器と比較すると、その性能、安全性
を保持したま5で、製品(人工臓器)重量を軽減せしめ
ている。The effect of the present invention is to reduce the weight of the product (artificial organ) while maintaining its performance and safety, compared to a steam sterilized artificial organ filled with water or an aqueous solution.
この結果、取扱い簡便さ、保管力簡易さ等の利点が得ら
れ、滅菌剤を使用しないため病院、患者等の使用の便宜
がかなえられている。As a result, advantages such as ease of handling and easy storage are obtained, and since no sterilizing agent is used, it is convenient for use in hospitals, patients, etc.
以下本発明を実施例により更に説明する。The present invention will be further explained below with reference to Examples.
実施例 l
内径260μ、外径320μのセルロース中空繊維11
000本を集束してポリカーボネイト製容器に収納した
のち、中空繊維束の両端をウレタン樹脂で固定した膜面
積1.57712の中空糸型人工臓器を組立てた。Example l Cellulose hollow fiber 11 with an inner diameter of 260μ and an outer diameter of 320μ
After 1,000 bundles were bundled and stored in a polycarbonate container, a hollow fiber type artificial organ with a membrane area of 1.57712 was assembled by fixing both ends of the hollow fiber bundle with urethane resin.
注射用蒸留水を使用してこの組立品(人工臓器)を洗浄
したのち、人工臓器の出入口をゴム栓により密封した。After washing this assembly (artificial organ) using distilled water for injection, the entrance and exit of the artificial organ was sealed with a rubber stopper.
このときの人工臓器の重量は900gであった。The weight of the artificial organ at this time was 900 g.
次に除菌空気1こより人工臓器の容器内空隙部分である
中空繊維内部(血液室)およびその外部(処理室)に残
存した蒸留水を除去した後、秤量したところ、その重量
は450gであった。Next, distilled water remaining inside the hollow fiber (blood chamber) and outside (processing chamber), which is the cavity inside the container of the artificial organ, was removed using one breath of sterilized air, and the weight was 450 g. Ta.
一刀、この状態での膜含水率を別途測定すると170%
であった。If you measure the water content of the membrane in this state separately, it will be 170%.
Met.
捉ってこのセルロ−ス中空繊維膜の最大含水率180%
にほぼ近い状態にあったことが判る。The maximum water content of this cellulose hollow fiber membrane is 180%.
It can be seen that the condition was almost close to that of .
上記滅菌前処理の済んだ人工臓器を通常の高圧飽和・蒸
気滅菌処理(115°C)こて30分間)したのち、冷
却を施した。The artificial organ that had undergone the above sterilization pretreatment was subjected to the usual high-pressure saturation/steam sterilization treatment (115°C, trowel for 30 minutes), and then cooled.
冷却1框において滅菌缶内圧は、冷却の進行とともに、
降圧するが、人工臓器中心部の温度に対応する飽和水蒸
気圧を超えない範囲で、一部乾燥熱空気と飽和水蒸気の
置換を施した。In one cooling tank, the internal pressure of the sterilization can increases as cooling progresses.
Partial replacement of dry hot air with saturated steam was performed to reduce the pressure but not exceed the saturated steam pressure corresponding to the temperature at the center of the artificial organ.
完全に室温まで降温し、冷却が完了した後、人口臓器を
熱滅菌機より、取りだして重量を測定したところ440
gであり、実質的に膜含水率(160%)を維持しなが
ら熱滅菌を完了した。After the temperature was completely lowered to room temperature and cooling was completed, the artificial organ was taken out from the heat sterilizer and its weight was measured.
g, and heat sterilization was completed while substantially maintaining the membrane water content (160%).
さらに上記人工臓器の性能(除水率、物質透過率)を実
測したところ除水率保持率91%および物質透過率(尿
素)保持率97%であり、従来の水又は水溶液の充填さ
れた熱滅菌人工臓器と実質的な差は認められなかった。Furthermore, when the performance (water removal rate, material permeability) of the artificial organ was actually measured, the water removal rate retention rate was 91% and the material permeability (urea) retention rate was 97%. No substantial difference was observed compared to sterile artificial organs.
またブライミング時における膜への気泡の残留も全く認
められなかった。Further, no air bubbles remained in the film during brimming.
実施例 2
実施例1と同様に、組立てたセルロース中空糸型人工臓
器を蒸留水で充分洗浄した後、50係グリセリン水溶液
を中空糸内部(血液室)および外部(処理室)に通液充
填し、中空糸膜をグリセリン水溶液にて膨潤せしめた。Example 2 In the same manner as in Example 1, after thoroughly washing the assembled cellulose hollow fiber artificial organ with distilled water, a 50% glycerin aqueous solution was passed through and filled inside the hollow fiber (blood chamber) and outside (processing chamber). , the hollow fiber membrane was swollen with an aqueous glycerin solution.
次に血液室および処理室内のグリセリン水溶液を除菌空
気で置換し、セルロース中空糸膜のみがグリセリン水溶
液で膨潤された人工臓器を得た。Next, the glycerin aqueous solution in the blood chamber and processing chamber was replaced with sterilized air to obtain an artificial organ in which only the cellulose hollow fiber membranes were swollen with the glycerin aqueous solution.
この状態の人工臓器の重量は430gであった(膜含水
率125%)。The weight of the artificial organ in this state was 430 g (membrane water content 125%).
また50%グリセリン水溶液に対する、セルロース中空
糸の最大膜含水率を別途実測すると130係であった。In addition, the maximum membrane water content of the cellulose hollow fibers was separately measured with respect to a 50% glycerin aqueous solution and was found to be 130.
上記滅菌前膨潤処理を終了した人工臓器(こ、実施例1
と同様に、高圧飽和滅菌を施し、冷却後、人工臓器の重
量を実測したところ400Iであった(膜含水率65%
)。Artificial organs that have undergone the above pre-sterilization swelling treatment (Example 1)
Similarly, after high-pressure saturation sterilization and cooling, the weight of the artificial organ was measured and found to be 400I (membrane water content 65%).
).
グリセリンがセルロース膜の寸法安定剤となるため、滅
菌後の膜含水率を、最大膜含水率の7/8〜1/2まで
低下させることが可能であった。Since glycerin acts as a dimensional stabilizer for the cellulose membrane, it was possible to reduce the membrane moisture content after sterilization to 7/8 to 1/2 of the maximum membrane moisture content.
上記人工臓器の性能を実測したところ、実施例1と同様
に従来の水又は水溶液の充填された熱滅菌処理人工臓器
と差異はなかった。When the performance of the artificial organ was actually measured, as in Example 1, there was no difference from the conventional heat-sterilized artificial organ filled with water or an aqueous solution.
実施例 3
両端部に血液導通口を有するセルロース膜チューブ(膜
千面積1.1m2)およびポリプロピレン製の網状膜支
持体とを積層し、スパイラル状に巻き、この膜チューブ
をポリカーボネート製の容器に収納し、更にシリコーン
エラストマーで両端に血液出入口を設けて膜チューブを
容器内に固定した。Example 3 A cellulose membrane tube (1,000 membrane area: 1.1 m2) having blood communication ports at both ends and a polypropylene network membrane support were laminated, wound in a spiral shape, and the membrane tube was stored in a polycarbonate container. In addition, blood ports were provided at both ends using silicone elastomer, and the membrane tube was fixed in the container.
かくしてコイル型人工腎臓を組立てた。In this way, a coil-type artificial kidney was assembled.
注射用蒸留水を血液導通口より、セルロースチューブ内
に通水し、膜を洗浄した後、30%ソルビトール水溶液
を送液した。Distilled water for injection was passed through the blood inlet into the cellulose tube to wash the membrane, and then a 30% aqueous sorbitol solution was delivered.
次に除菌空気にてチューブ内に残存しているソルビトー
ル水溶液を追い出し、セルロース膜チューブのみがソル
ビトール水溶液で膨潤されたコイル型人工腎臓を得た。Next, the sorbitol aqueous solution remaining in the tube was expelled with sterilized air to obtain a coiled artificial kidney in which only the cellulose membrane tube was swollen with the sorbitol aqueous solution.
膜含水率の実測値は130%であり、重量は720gで
あった。The measured value of the membrane water content was 130%, and the weight was 720 g.
−力、30係ソルビトールに対する同一セルロース膜の
最大膜含水率は140係であった。The maximum membrane water content of the same cellulose membrane for sorbitol was 140.
実施例1と同様に高圧飽和蒸気滅菌後、冷却した後、重
量を計量したところ720gであった(膜含水率130
%)。After high-pressure saturated steam sterilization and cooling in the same manner as in Example 1, the weight was measured to be 720 g (membrane water content: 130 g).
%).
上記人工腎臓の諸物性値(除水率、物質透過率、血液抵
抗、血液残留度)と、同−膜よりなるコイル型人工腎臓
とを、熱水中に浸漬させた状態で高圧滅菌処理(115
°Cで30分間)を施した後の諸物性値とを比較したが
、実質的な相違は認められなかった。The physical properties of the artificial kidney described above (water removal rate, material permeability, blood resistance, blood residual degree) and the coiled artificial kidney made of the same membrane were immersed in hot water and subjected to high-pressure sterilization ( 115
When comparing the various physical property values after the test (at 30°C for 30 minutes), no substantial differences were observed.
実施例 4
平均粒径650μの球状活性炭150gをポリビニール
アルコール膜でマイクロカプセル化して、ポリカーボネ
ートおよびポリプロピレン製容器に収納し、両端に活性
炭の漏出防止スクリーンおよび血液分配集合部を取り付
けた人工臓器を製造した。Example 4 An artificial organ was manufactured by micro-encapsulating 150 g of spherical activated carbon with an average particle size of 650 μm with a polyvinyl alcohol membrane, storing it in a container made of polycarbonate and polypropylene, and attaching an activated carbon leak-prevention screen and a blood distribution collection unit to both ends. did.
まず、注射用蒸留水を人工臓器内に通水洗浄し、活性炭
および皮膜であるポリビニールアルコールを充分水で膨
潤させた。First, distilled water for injection was passed through the artificial organ to wash it, and the activated carbon and the polyvinyl alcohol film were sufficiently swollen with water.
次に血液分配部より除菌空気を吹き込み、人工臓器容器
内空隙部の充填水150gを血液集合部より除去するこ
とにより、活性炭および皮膜のみが水で膨潤された人工
臓器を得た。Next, sterilized air was blown through the blood distribution section and 150 g of water filled in the cavity inside the artificial organ container was removed from the blood collection section, thereby obtaining an artificial organ in which only the activated carbon and the membrane were swollen with water.
この状態での重量は440gであり、別途測定した活性
炭および皮膜の最大膜および活性含水率に達していた。The weight in this state was 440 g, which reached the maximum film and active water content of the activated carbon and film that were measured separately.
次いで実施例1と同様に、高圧蒸気滅菌処理を実施し、
冷却後、人工臓器の重量を実測し440gを得た。Then, in the same manner as in Example 1, high-pressure steam sterilization was performed,
After cooling, the weight of the artificial organ was measured and the weight was 440 g.
上記人工臓器の吸着能力、プライミング操作時の気泡残
留度、血液抵抗、血液残量等を測定したところ、予め水
を充填して、高圧蒸気滅菌した同一人工臓器に比べ実質
的な差は認められなかった。When we measured the adsorption capacity, residual air bubbles during priming, blood resistance, blood remaining amount, etc. of the artificial organ, we found no substantial difference compared to the same artificial organ that had been pre-filled with water and sterilized with high-pressure steam. There wasn't.
従って、水が充填していない人工臓器が得られることが
明らかとなった。Therefore, it has become clear that an artificial organ not filled with water can be obtained.
Claims (1)
際し、予め人工臓器を構成する膜機能部を水、水溶液ま
たは水蒸気にて膨潤させ、次いで該人工臓器に飽和水蒸
気雰囲気下で高圧蒸気滅菌を施し、しかる後、該人工臓
器への水の凝着を抑えながら、必要に応じて除湿・水分
除去を施しながら、冷却せしめることからなる膜機能部
が実質的に水または水溶液で膨潤させかつ該人工臓器の
容器及び内部空隙が水または水溶液で充填されていない
ことを特徴とする高圧蒸気滅菌された人工臓器の製造方
法。1. When subjecting a heat-resistant artificial organ to high-pressure steam sterilization, the membrane functional part constituting the artificial organ is swollen in advance with water, an aqueous solution, or steam, and then the artificial organ is subjected to high-pressure steam sterilization in a saturated steam atmosphere. Thereafter, the membrane function part, which consists of cooling the artificial organ while suppressing the adhesion of water to the artificial organ and performing dehumidification and water removal as necessary, is substantially swollen with water or an aqueous solution, and the artificial organ is cooled. A method for producing an artificial organ sterilized by high-pressure steam, characterized in that the container and internal cavity of the organ are not filled with water or an aqueous solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54089319A JPS5931345B2 (en) | 1979-07-16 | 1979-07-16 | Method for producing artificial organs sterilized by high-pressure steam |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54089319A JPS5931345B2 (en) | 1979-07-16 | 1979-07-16 | Method for producing artificial organs sterilized by high-pressure steam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5613946A JPS5613946A (en) | 1981-02-10 |
| JPS5931345B2 true JPS5931345B2 (en) | 1984-08-01 |
Family
ID=13967338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54089319A Expired JPS5931345B2 (en) | 1979-07-16 | 1979-07-16 | Method for producing artificial organs sterilized by high-pressure steam |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5931345B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6395541U (en) * | 1986-12-11 | 1988-06-20 | ||
| JPS63125941U (en) * | 1987-02-09 | 1988-08-17 | ||
| JPS63160748U (en) * | 1987-04-07 | 1988-10-20 | ||
| JPH04339U (en) * | 1990-04-12 | 1992-01-06 | ||
| JPH0638836U (en) * | 1992-03-11 | 1994-05-24 | 洋子 木場 | Washing container |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6099260A (en) * | 1983-11-02 | 1985-06-03 | 東洋紡績株式会社 | Autoclave pasturization of cellulose ester hollow fiber typeseparation membrane |
| JPS60190204A (en) * | 1984-03-09 | 1985-09-27 | Sumitomo Bakelite Co Ltd | Modification of polysulfone resin membrane |
| JP2769712B2 (en) * | 1989-03-22 | 1998-06-25 | 川澄化学工業株式会社 | Manufacturing method of fluid treatment device |
| JP2728814B2 (en) * | 1991-09-06 | 1998-03-18 | 株式会社クラレ | Cardiopulmonary support equipment |
| JPH07148251A (en) * | 1993-11-30 | 1995-06-13 | Toyobo Co Ltd | Method for sterilizing dialyzer for blood purification and sterilized dialyzer for blood purification |
-
1979
- 1979-07-16 JP JP54089319A patent/JPS5931345B2/en not_active Expired
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6395541U (en) * | 1986-12-11 | 1988-06-20 | ||
| JPS63125941U (en) * | 1987-02-09 | 1988-08-17 | ||
| JPS63160748U (en) * | 1987-04-07 | 1988-10-20 | ||
| JPH04339U (en) * | 1990-04-12 | 1992-01-06 | ||
| JPH0638836U (en) * | 1992-03-11 | 1994-05-24 | 洋子 木場 | Washing container |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5613946A (en) | 1981-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2599204B2 (en) | Hemodialysis agent | |
| US4148606A (en) | Sterilization of dialyzer | |
| EP2590687B1 (en) | Use of a sterilization agent for enhancing hemocompatibility | |
| JPS5931345B2 (en) | Method for producing artificial organs sterilized by high-pressure steam | |
| JPS59211459A (en) | Pasturization of blood treating device | |
| US4176070A (en) | Semi-permeable membranes of regenerated cuprammonium cellulose and method for heat sterilization thereof in physiological saline | |
| JPS6213022B2 (en) | ||
| JP4129393B2 (en) | Extracorporeal treatment apparatus for blood or plasma containing wet semipermeable membrane and method for producing the same | |
| JP4738729B2 (en) | Sterilization packaging method for hollow fiber blood processor | |
| JPS6010735B2 (en) | Method for manufacturing a sterile hollow fiber artificial kidney | |
| JP2779257B2 (en) | Blood processing equipment sterilization method | |
| JPS609818B2 (en) | artificial organs | |
| JPS603497B2 (en) | Method for manufacturing heat-sterilized artificial organs | |
| JPS607496B2 (en) | Heat sterilization method for artificial kidneys | |
| JPH0288074A (en) | Manufacture of blood treating device | |
| JP2629084B2 (en) | Preservation method of membrane oxygenator | |
| JPS594136B2 (en) | Method for manufacturing heat-sterilized artificial organs | |
| JPS6250150B2 (en) | ||
| JPS606660B2 (en) | Method for manufacturing sterile artificial organs | |
| JPH07148251A (en) | Method for sterilizing dialyzer for blood purification and sterilized dialyzer for blood purification | |
| JPS6312631B2 (en) | ||
| JPS60165959A (en) | Sterilization of artificial organ | |
| JPH0422585B2 (en) | ||
| Shaldon | 22 years of experience with reuse of dialysers. | |
| JPS5934379B2 (en) | Method for manufacturing heat sterilized artificial kidney |